- Article metrics
- Last updated: Fri, 26 Apr 2024 16:57:27 Z
A phase 3 clinical trial with ISIS-TTRRx, a 2nd-generation antisense oligonucleotide targeting transthyretin (TTR), for the treatment of TTR amyloid cardiomyopathy
Access & Citations
-
- 880
- Article Accesses
-
- 0
- Web of Science
-
- 1
- CrossRef
Citation counts are provided from Web of Science and CrossRef. The counts may vary by service, and are reliant on the availability of their data. Counts will update daily once available.